NASDAQ:RLAY - Nasdaq - US75943R1023 - Common Stock - Currency: USD
3.25
-0.04 (-1.22%)
The current stock price of RLAY is 3.25 USD. In the past month the price increased by 41.92%. In the past year, price decreased by -53.84%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.33 | 351.09B | ||
AMGN | AMGEN INC | 13.55 | 151.20B | ||
GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.57B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
NTRA | NATERA INC | N/A | 21.30B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
BIIB | BIOGEN INC | 7.81 | 18.10B |
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is headquartered in Cambridge, Massachusetts and currently employs 261 full-time employees. The company went IPO on 2020-07-16. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. The company is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
RELAY THERAPEUTICS INC
399 Binney Street, 2nd Floor
Cambridge MASSACHUSETTS 02139 US
CEO: Sanjiv K. Patel
Employees: 304
Phone: 16173708837
The current stock price of RLAY is 3.25 USD. The price decreased by -1.22% in the last trading session.
The exchange symbol of RELAY THERAPEUTICS INC is RLAY and it is listed on the Nasdaq exchange.
RLAY stock is listed on the Nasdaq exchange.
19 analysts have analysed RLAY and the average price target is 17.34 USD. This implies a price increase of 433.54% is expected in the next year compared to the current price of 3.25. Check the RELAY THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
RELAY THERAPEUTICS INC (RLAY) has a market capitalization of 554.09M USD. This makes RLAY a Small Cap stock.
RELAY THERAPEUTICS INC (RLAY) currently has 304 employees.
RELAY THERAPEUTICS INC (RLAY) has a support level at 3.09 and a resistance level at 3.26. Check the full technical report for a detailed analysis of RLAY support and resistance levels.
The Revenue of RELAY THERAPEUTICS INC (RLAY) is expected to decline by -70.15% in the next year. Check the estimates tab for more information on the RLAY EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
RLAY does not pay a dividend.
RELAY THERAPEUTICS INC (RLAY) will report earnings on 2025-05-05, after the market close.
RELAY THERAPEUTICS INC (RLAY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.39).
The outstanding short interest for RELAY THERAPEUTICS INC (RLAY) is 13.4% of its float. Check the ownership tab for more information on the RLAY short interest.
ChartMill assigns a technical rating of 2 / 10 to RLAY. When comparing the yearly performance of all stocks, RLAY is a bad performer in the overall market: 90.36% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to RLAY. No worries on liquidiy or solvency for RLAY as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months RLAY reported a non-GAAP Earnings per Share(EPS) of -2.39. The EPS increased by 14.64% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -38.76% | ||
ROE | -43.42% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 84% to RLAY. The Buy consensus is the average rating of analysts ratings from 19 analysts.
For the next year, analysts expect an EPS growth of 11.31% and a revenue growth -70.15% for RLAY